Fortress Biotech Inc
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Fortress Biotech's stock with a target price of $26.25, indicating significant growth potential.
Financial Health
Fortress Biotech is generating solid revenue and cash flow, indicating a strong financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring FBIO
Thrill & Excitement Fund
Ready for an investing adventure? This collection features carefully selected stocks with explosive growth potential. Our professional analysts have identified companies at the cutting edge of space tourism, biotech breakthroughs, and digital gaming — all poised to potentially redefine their industries.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diversified development pipeline
The company advances multiple programmes across subsidiaries, so positive trial news or licences can materially shift prospects — though outcomes vary and setbacks are common.
Clinical catalysts ahead
Upcoming data readouts or regulatory steps can create significant share-price movement; these catalysts bring opportunity but also heightened binary risk.
Capital and dilution risk
As a small-cap biotech, Fortress may need additional funding to progress its pipeline, which could dilute existing shareholders and affect share price.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
